Anti-Stella DPPA3 Antibody

Stella was initially identified in primordial germ cells and pre-implantation embryos whose expression as a maternal factor is important in early embryonic development but is not required for germ cell specification in mice. In humans, Stella is thought to be a marker for pluripotency in embryonic stem (ES) cells as its expression is observed in primordial germ cells of both sexes and germ cell tumors but not in normal somatic tissues. However, in ES cell colonies, heterogeneous expression of Stella was seen in high throughput in situ hybridization assays, indicating that higher levels of complexity exist in otherwise thought to be undifferentiated ES cells. At least two distinct isoforms of Stella are known to exist.

Stella antibody was raised against a 13 amino acid synthetic peptide from near the carboxy terminus of human Stella. The immunogen is located within the last 50 amino acids of Stella.

Primordial germ cell (PGCs) -specific protein involved in epigenetic chromatin reprogramming in the zygote following fertilization. In zygotes, DNA demethylation occurs selectively in the paternal pronucleus before the first cell division, while the adjacent maternal pronucleus and certain paternally-imprinted loci are protected from this process. Participates in protection of DNA methylation in the maternal pronucleus by preventing conversion of 5mC to 5hmC: specifically recognizes and binds histone H3 dimethylated at 'Lys-9' (H3K9me2) on maternal genome, and protects maternal genome from TET3-mediated conversion to 5hmC and subsequent DNA demethylation. Does not bind paternal chromatin, which is mainly packed into protamine and does not contain much H3K9me2 mark. Also protects imprinted loci that are marked with H3K9me2 in mature sperm from DNA demethylation in early embryogenesis. May be important for the totipotent/pluripotent states continuing through preimplantation development. Also involved in chromatin condensation in oocytogenesis (By similarity) . .

Stella antibody can be stored at 4°C for three months and -20°C, stable for up to one year. Avoid repeated freeze-thaw cycles. Antibodies should not be exposed to prolonged high temperatures.